GlassScriptPhysician profile
Daniel Leonard Bowers
NPI 1417113952
$1,337.28
in general payments reported to CMS, 2019-2025
23 companies · $446 in 2025
The $446 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.52 · 2023: $299 · 2024: $575 · 2025: $446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,319.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $232.67 | 2023-2025 | |
| Karyopharm Therapeutics INC. | $169.15 | 2023-2025 | Xpovio |
| Gilead Sciences, INC. | $122.35 | 2023-2025 | Trodelvy |
| Incyte Corporation | $89.10 | 2023-2025 | Jakafi, Niktimvo |
| Sobi, INC | $77.51 | 2024-2025 | |
| Abbvie INC. | $74.83 | 2024-2025 | |
| Genmab U.S., INC. | $65.53 | 2025 | Epkinly |
| Exelixis INC. | $64.22 | 2024-2025 | Cabometyx |
| Mirati Therapeutics, INC. | $54.07 | 2023-2024 | Krazati |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.18 | 2025 | |
| Celgene Corporation | $47.39 | 2023 | Pomalyst |
| Coherus Oncology, INC. | $45.97 | 2024 | |
| Geron Corporation | $26.36 | 2025 | Rytelo |
| Immunogen, INC. | $23.27 | 2023 | Elahere |
| Aveo Pharmaceuticals, INC. | $23.22 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $22.91 | 2023 | Rezlidhia, Tavalisse |
| Recordati_rare_diseases_inc. | $22.80 | 2023 | Sylvant |
| Morphosys, US INC. | $22.48 | 2024 | Monjuvi |
| Alexion Pharmaceuticals, INC. | $22.19 | 2023 | Ultomiris |
| Beone Medicines USA, INC. | $22.02 | 2025 | Tevimbra |
| Daiichi Sankyo INC. | $21.17 | 2024 | Vanflyta |
| Pharmacosmos Therapeutics INC. | $18.37 | 2024 | Cosela |
| Zimmer Biomet Holdings, INC. | $17.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Bowers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.